The NKp46 protein is found on resting and activated natural killer (NK) cells and is involved in the recognition of malignant and infected cells. The expression of NKp46 is believed to precede that of DX5 in early NK cell development. We show that this is not the case in the bone marrow (BM). Here, NKp46 is predominantly expressed after DX5, whereas the liver harbors a subpopulation that expresses NKp46 but not DX5. NK cell precursors in the liver show much lower levels of Eomesodermin than NK cell precursors in the BM, although they express higher levels of granzymes and unlike the NK cell precursors in the BM are fully able to degranulate and produce interferon gamma (IFN-γ) . The development of NK cells thus differs between the two organs. This needs to be considered when using NKp46 and DX5 as NK cell markers and when performing NK cell-specific gene deletion in Ncr1 transgenic mice.
INTRODUCTION
Natural killer (NK) cells are innate lymphoid cells originating from a common lymphoid progenitor in the bone marrow (BM).
1,2 During development and maturation, NK cells acquire different surface markers in a strict sequential order defining distinct developmental stages. The differentiation from the ID2-expressing pre-pro NK cell 3 to NK precursors is characterized by the acquisition of the IL-2Rβ chain (CD122). Subsequently, immature NK cells initiate the expression of the pan-NK cell marker NK1.1, followed by α2 integrin (CD49b), also referred as DX5. [4] [5] [6] Further maturation steps are predominantly taking place in the periphery, where classical NK cell maturation is dissected in distinct stages on the basis of CD27, CD11b and KLRG1 expression. 4, 7, 8 The liver represents an exceptional site, where two major NK cell populations are found. Besides the conventional TRAIL − DX5 + NK cells the liver harbors a TRAIL + DX5 − population that does not depend on the transcription factors Eomesodermin (Eomes) and Nfil3. [9] [10] [11] The discovery of NKp46 (NCR1, CD335) was a milestone in NK cell biology, as it is an exclusive NK cell marker found in mice and men. It is the current concept that NKp46 is expressed at the immature NK cell stage preceding the expression of DX5. 5, 6 We here provide evidence for distinct NK developmental patterns in liver and BM based on the unexpected discovery that in contrast to the liver a major NK cell population in the BM expresses DX5 but not NKp46. Figure S1A ). This observation was verified in RosatdRFP-Ncr1-iCre tg reporter mice (Supplementary Figure S2A) and heterozygous mice expressing a GFP reporter cassette instead of exons 5-7 of Ncr1 (Ncr1 +/gfp ) of BALB/c and C57BL/6 background (Supplementary Figures S2C-F) . This finding shows the general validity of our data beyond mouse background and clearly opposes previous reports that described NKp46 to be expressed before DX5 in the BM. 5, 6 One explanation for this discrepancy is the fact that NKp46 expression was predominantly studied in the liver, 5 while we focused on conventional NK cells in the BM. Indeed, when we compared liver and BM side by side, we found that the acquisition of NKp46 and DX5 expression showed different patterns. With the exception of a minor subpopulation (2%) liver NK cells express NKp46 in the absence of DX5 (Figure 1b and Supplementary Figure S1B ) unlike the situation in the BM. Analysis of Rosa-tdRFP-Ncr1-iCre tg mice verified these results (Supplementary Figure S2B) .
RESULTS AND DISCUSSION
These findings suggest that NKp46 is a marker of mature rather than immature NK cells in the BM. To test this hypothesis, we investigated the maturation status of the individual subpopulations by analyzing the expression of CD27 and CD11b (Figures 1c and d ), NKG2D and Ly-49D (Supplementary Figure S4) . In addition, we studied CD49a that correlates with TRAIL expression, which is considered as a hallmark of hepatic NK cells 11, 12 and is transiently expressed during NK cell development in the BM (Figures 1c and d ). According to the concept that NKp46 is an indicator of mature NK cells in the BM we observed cytokine-induced interferon Figure S6C) . In the BM NK1.1-receptor crosslinking induced degranulation (CD107a expression) primarily in DX5 + NKp46 + cells, whereas in the liver all NK subpopulations showed a substantial degree of degranulation, which was most prominent in DX5 − NKp46 + NK cells (Figure 2f ). In summary, our experiments raise the intriguing possibility that development of NK cells in the BM proceeds by a pathway different from that in the liver. The chronology of expression of DX5 and NKp46 differs in BM-derived NK cells from the paradigm in the liver, 5, 6 although the difference has not previously attracted attention. We propose a revised model for the sequential acquisition of NK cell markers along the pathway from pre-pro-NK cells (stage I) to fully functional NK effector cells (stage VII) in the BM (see Figure 2g) . We suggest that this might be the conventional pathway that has been amended in the liver by the earlier expression of NKp46, possibly as a result of the need to target pathogens in a NKp46-dependent manner.
The new pathway of NK cell development in the BM should be taken into account in the design and evaluation of experiments that employ NKp46 or DX5 as NK cell markers or that use Ncr1-Cre mice as the state-of-the-art model for NK cell-specific gene deletion. 6, 16 
MATERIALS AND METHODS Mice
The following mice (8-10 weeks old) were used: C57BL/6 wild-type mice (CD45. Organ preparation and cell stimulation Liver lymphocytes were prepared as previously published. 18 In brief, the liver was perfused via the portal vein with 5-10 ml sterile phosphatebuffered saline to remove peripheral blood lymphocytes. After disruption of the liver through a nylon filter and several washing steps, lymphocytes were separated from hepatocytes using a 37.5% Percoll gradient (GE Healthcare, Cleveland, OH, USA). BM cells were isolated by flushing femur and tibia with 5 ml sterile phosphate-buffered saline followed by repeated resuspension using a 25 G needle.
Cell suspensions were stimulated for 4 h with 5000 U ml −1 rhIL-2 (Novartis, Basel, Switzerland), 5 ng ml −1 rmIL-12 (R&D, Minneapolis, MN, USA) and 50 ng ml −1 rmIL-15 (PeproTech, Rocky Hill, NJ, USA). For α-NK1.1 crosslinking studies, FACS tubes were coated o/n with 10 μg ml −1 goat-anti mouse-IgG (BD, Franklin Lakes, NJ, USA) at 4°C. On the next day, the tubes were washed and incubated with mouse anti-NK1.1 (PK136, 10 μg ml 
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.04 for Windows (GraphPad Software; http://www.graphpad.com). Where ANOVA showed a statistical difference, Tukey's multiple comparison testing was applied. The significance level for all tests was set to 0.05 and P-values were two tailed (*Po 0.05; **Po0.01; ***Po0.001).
